Plasma apolipoprotein A1 associates with age at onset and motor severity in early Parkinson's disease patients.

ABSTRACT:

Background

Development of robust plasma-based biomarkers in Parkinson's disease (PD) could lead to new approaches for identifying those at risk for PD and developing novel therapies. Here, we validate plasma apolipoprotein A1 (ApoA1) as a correlate of age at onset and motor severity in PD.

Methods

Plasma ApoA1 and high-density lipoprotein at baseline, 6 months, and 12 months were measured in 254 research volunteers (154 patients with PD and 100 normal controls) enrolled in the Parkinson's Progression Markers Initiative (PPMI) study.

Results

Lower baseline plasma ApoA1 levels associate with an earlier age at PD onset in early-stage, drug-naïve PPMI PD patients (P = 0.023). Moreover, lower baseline ApoA1 levels trend toward association with worse motor severity in PPMI

SUBMITTER: Swanson CR 

PROVIDER: S-EPMC4609229 | biostudies-literature | 2015 Oct

REPOSITORIES: biostudies-literature